1、Accelerate Drug Target Validation: Customized Cas9 Gene-Edited Cell Line Construction for Precise Preclinical Efficacy Evaluation

• Addressing the core pain points of pharmaceutical companies: Traditional gene editing technologies feature long cycles, low efficiency and inaccurate models, leading to delayed target validation and slowed drug R&D progress.
• Value Proposition：Providing highly efficient and customizable Cas9 gene-edited cell lines that accurately simulate disease targets, shortening drug screening cycles by more than 50% and reducing the risk of preclinical failure.

2、Service Overview

Positioning: Cas9 gene-edited cell lines are core tools for preclinical drug target validation and mechanism research, directly influencing the evaluation of the efficacy and safety of drug candidates.

Industry Pain Point：

1. Unstable gene editing efficiency and time-consuming monoclonal screening (3-6 months).
2. Insufficient functional verification of edited cells, failing to truly reflect the biological characteristics of targets.

Solutions:

Precisely construct gene knockout/overexpression cell lines via CRISPR-Cas9 technology, and combine with functional verification to provide in vitro models that highly recapitulate disease mechanisms for efficacy evaluation, accelerating the entire process from target discovery to IND application.

3、Our Services

Technical Solutions Categorized by Application Scenario：

4、Technical Platforms and Advantages

Core Technical Platforms:

1. CRISPR-Cas9 Tool Cell Platform:
   • Adopt high-transfection efficiency tool cells such as 293T and HELa, increasing monoclonal formation rate by 40%.
   • Support single/double gene editing with an off-target rate of <0.5% (verified by whole-genome sequencing).

2. Stable Cell Line Construction Platform:

• Lentiviral/electroporation delivery system with a stable transfection efficiency of 90%, supporting dual fluorescent/drug-resistant labeling.

Differentiated Advantages:

• Precision and high efficiency: Targeted design covers more than 1000 tumor-associated genes, shortening the editing cycle to 8-12 weeks (industry average: 12-16 weeks).
• Closed-loop functional verification: Simultaneously provide phenotypic detection such as cell proliferation, apoptosis and migration to ensure the pharmacological relevance of edited models.

5、Service Process

6、Quality Control and Compliance

• Standard Compliance:
  • Experimental procedures comply with GLP-aligned specifications (ISO 9001 quality management system) with traceable data.
• Quality Control:

1. Vector Construction: Sanger sequencing to verify sgRNA activity.
2. Monoclonal Screening: STR identification to ensure no cross-contamination of cells.
3. Functional Verification: Positive/negative controls included in each batch of experiments.

• Data Integrity:
  • All raw data (sequencing peak maps, flow cytometry plots) are retained to support third-party audits.

7、Case Studies

Case 1: Construction of HER2 Overexpression Breast Cancer Model

• Customer Demand: Verify the efficacy of anti-HER2 monoclonal antibodies on trastuzumab-resistant cells.
• Solution: Construct HER2-overexpressing MCF-7 stable cell lines and introduce Luciferase labeling simultaneously.
• Results:

• Editing efficiency: 92% (verified by WB).
• Efficacy verification: IC50 of drug-resistant cells increased by 5 times, with >90% consistency with clinical data.

Case 2: EGFR T790M Mutant Lung Cancer Model

• Application: Evaluate the sensitivity of the third-generation EGFR inhibitor osimertinib.
• Achievements: Mutant cells showed significantly increased sensitivity to osimertinib (TGI 78%), supporting the customer’s IND application.

8、Cooperation Advantages

1. Flexible Customization: Support cell line construction from single-gene editing to multi-pathway synergy models, adapting to drug types such as antibodies, small molecules and cell therapy.
2. End-to-End Support: Cover vector design → cell construction → phenotypic verification → efficacy testing, reducing cross-platform collaboration costs.
3. Timeliness Guarantee: Compress the cycle of expedited projects by 30% and launch urgent requests within 15 days.

9、FAQ

Q1: Do you support primary cell editing?

A: Not at present. The current service is limited to immortalized cell lines (e.g., HEK293, Hela, tumor cell lines, etc.) to ensure editing efficiency and stability.

Q2: Can you provide GLP-certified reports?

A: We implement GLP-aligned standards but have not yet obtained official certification. Complete raw data is provided for all experiments to support internal audits of pharmaceutical companies.

Q3: Can the delivery cycle be further shortened?

A: Expedited projects can be accelerated through the pre-constructed vector library, with a minimum cycle of 6 weeks (additional evaluation of target feasibility is required).

10、Laboratory Highlights

Core Equipment:

• Automated Monoclonal Picker (200 clones/hour efficiency)
• High-Throughput Sequencing Verification Platform (Illumina MiSeq)
• Real-Time Cell Imaging System (dynamic phenotypic monitoring)

View More

11、Contact Us

Consult Now:

• 📧Email:3691125803@qq.com
• 📞Tel: +86 18802035152

Resource Download:

• Download the Cas9 Gene Editing Technology Manual
• Book a free technical consultation